RESUMO
The use of eponyms in neurology remains controversial, and important questions have been raised about their appropriateness. Different approaches have been taken, with some eponyms being excluded, others replaced, and new ones being created. An example is Hallervorden-Spatz syndrome, which has been replaced by neurodegeneration with brain iron accuulatium (NBIA). Amiothoplic lateral sclerosys (ALS), for which the eponym is Charcot's disease, has been replaced in the USA by Lou Gehrig's disease. Guillain-Barré syndrome (GBS) is an eponym that is still the subject of controversy, and various different names are associated with it. Finally,restless legs syndrome (RLS), which was for years known as Ekbom's syndrome, has been rechristened as RLS/Willis-Ekbom syndrome.
Assuntos
Epônimos , Doenças do Sistema Nervoso/história , Esclerose Lateral Amiotrófica/história , Síndrome de Guillain-Barré/história , História do Século XVII , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Distúrbios do Metabolismo do Ferro/história , Distrofias Neuroaxonais/história , Síndrome das Pernas Inquietas/históriaRESUMO
ABSTRACT The use of eponyms in neurology remains controversial, and important questions have been raised about their appropriateness. Different approaches have been taken, with some eponyms being excluded, others replaced, and new ones being created. An example is Hallervorden-Spatz syndrome, which has been replaced by neurodegeneration with brain iron accuulatium (NBIA). Amiothoplic lateral sclerosys (ALS), for which the eponym is Charcot’s disease, has been replaced in the USA by Lou Gehrig’s disease. Guillain-Barré syndrome (GBS) is an eponym that is still the subject of controversy, and various different names are associated with it. Finally,restless legs syndrome (RLS), which was for years known as Ekbom’s syndrome, has been rechristened as RLS/Willis-Ekbom syndrome.
RESUMO O uso de epônimos em neurologia permanece ainda controverso nos dias de hoje, e importantes questões tem sido levantadas sobre o seu uso. Diferentes abordagens têm sido feitas, com a exclusão de alguns epônimos, modificação ou criação de outros. Um exemplo é a síndrome de Hallervorden-Spatz (SHS), cuja denominação foi modificada para neurodegeneração associada com acúmulo de ferro cerebral (NBIA). Outro exemplo é a esclerose lateral amiotrófica (ELA), cujo epônimo doença de Charcot, tem sido substituído nos EUA por doença de Lou Gehring. A síndrome de Guillain-Barré (SGB) representa um epônimo em que a controvérsia persiste, e diferentes nomes têm sido associados ao clássico SGB. Por fim, a síndrome das pernas inquietas (SPI), que por anos foi definida como síndrome de Ekbom, e que na atualidade foi definida como SPI/síndrome de Willis-Ekbom.
Assuntos
Humanos , História do Século XVII , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Epônimos , Doenças do Sistema Nervoso/história , Síndrome das Pernas Inquietas/história , Distrofias Neuroaxonais/história , Distúrbios do Metabolismo do Ferro/história , Síndrome de Guillain-Barré/história , Esclerose Lateral Amiotrófica/históriaRESUMO
Thomas de Quincey, a British writer of 19th century, suffered insomnia from the age of 17 years. In his famous "Confessions of an English-Opium Eater" (1822), he described a symptomatology that could concord with restless legs syndrome long before he became addicted to opium. In this report, we analyze his clinical description and the circumstances leading to his opium addiction.
Assuntos
Pessoas Famosas , Transtornos Relacionados ao Uso de Opioides/história , Ópio , Síndrome das Pernas Inquietas/história , Inglaterra , História do Século XIX , Humanos , Masculino , Transtornos Relacionados ao Uso de Opioides/complicações , Publicações/história , Síndrome das Pernas Inquietas/etiologia , AutorrevelaçãoRESUMO
The authors provide an historical review of restless legs syndrome, emphasizing the contribution of Professor Karl-Axel Ekbom, the Swedish neurologist who made the first detailed clinical description of this disease.